Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11028832rdf:typepubmed:Citationlld:pubmed
pubmed-article:11028832lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0016053lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C1556085lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0360055lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C2917412lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0679932lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0063322lld:lifeskim
pubmed-article:11028832lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:11028832pubmed:dateCreated2000-11-3lld:pubmed
pubmed-article:11028832pubmed:abstractTextBased on a potential role for serotonin receptors in fibromyalgia, we investigated the efficacy and tolerability of treatment with tropisetron, a highly selective, competitive inhibitor of the 5-HT3 receptor.lld:pubmed
pubmed-article:11028832pubmed:languageenglld:pubmed
pubmed-article:11028832pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:citationSubsetIMlld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11028832pubmed:statusMEDLINElld:pubmed
pubmed-article:11028832pubmed:issn0301-3847lld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:MüllerWWlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:SpäthMMlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:ZöllerBBlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:Lautenschläge...lld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:PongratzDDlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:PeterH HHHlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:StrateCClld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:AlteaEElld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:BrückleWWlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:FärberLLlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:NeeckGGlld:pubmed
pubmed-article:11028832pubmed:authorpubmed-author:KötterIIlld:pubmed
pubmed-article:11028832pubmed:issnTypePrintlld:pubmed
pubmed-article:11028832pubmed:volume113lld:pubmed
pubmed-article:11028832pubmed:ownerNLMlld:pubmed
pubmed-article:11028832pubmed:authorsCompleteYlld:pubmed
pubmed-article:11028832pubmed:pagination49-54lld:pubmed
pubmed-article:11028832pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:meshHeadingpubmed-meshheading:11028832...lld:pubmed
pubmed-article:11028832pubmed:year2000lld:pubmed
pubmed-article:11028832pubmed:articleTitleEfficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.lld:pubmed
pubmed-article:11028832pubmed:affiliationInstitut für Pharmakologie der Universität Regensburg, Germany. lothar.faerber@pharma.novartis.comlld:pubmed
pubmed-article:11028832pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11028832pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11028832pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11028832pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:11028832pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11028832lld:pubmed